|
CSTL
|
Castle Biosciences, Inc.
|
US
|
NASDAQ
|
|
CTSO
|
Cytosorbents Corporation
|
US
|
NASDAQ
|
|
CYTH
|
Cyclo Therapeutics, Inc.
|
US
|
NASDAQ
|
|
DVA
|
DaVita HealthCare Partners Inc.
|
US
|
NYSE
|
|
ELEV
|
Elevation Oncology, Inc.
|
US
|
NASDAQ
|
|
ELMD
|
Electromed, Inc.
|
US
|
AMEX
|
|
ENLV
|
Enlivex Therapeutics Ltd.
|
US
|
NASDAQ
|
|
EOLS
|
Evolus, Inc.
|
US
|
NASDAQ
|
|
ERNA
|
Eterna Therapeutics Inc.
|
US
|
NASDAQ
|
|
ERYP
|
Erytech Pharma S.A.
|
US
|
NASDAQ
|
|
ESTA
|
Establishment Labs Holdings Inc.
|
US
|
NASDAQ
|
|
EVAX
|
Evaxion Biotech A/S
|
US
|
NASDAQ
|
|
EW
|
Edwards Lifesciences Corporation
|
US
|
NYSE
|
|
FBIO
|
Fortress Biotech, Inc.
|
US
|
NASDAQ
|
|
FBIOP
|
Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
|
US
|
NASDAQ
|
|
FMS
|
Fresenius Medical Care AG
|
US
|
NYSE
|
|
FNCH
|
Finch Therapeutics Group, Inc.
|
US
|
NASDAQ
|
|
FSTX
|
F-star Therapeutics, Inc.
|
US
|
NASDAQ
|
|
GCTK
|
GlucoTrack, Inc.
|
US
|
NASDAQ
|
|
GLS
|
Gelesis Holdings, Inc.
|
US
|
NYSE
|